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IL-10 is a potent immunoregulatory and anti-inflammatory cytokine. However, ther-
apeutic trials in chronic inflammation have been largely disappointing. It is well estab-
lished that IL-10 can inhibit Th1 and Th2 cytokine production via indirect effects on APC.
Less data are available about the influence of IL-10 on IL-17 production, a cytokine which
has been recently linked to chronic inflammation. Furthermore, there are only few reports
about a direct effect of IL-10 on T cells. We demonstrate here that IL-10 can directly
interfere with TCR-induced IFN-c production in freshly isolated memory T cells in the
absence of APC. This effect was independent of the previously described effects of IL-10 on
T cells, namely inhibition of IL-2 production and inhibition of CD28 signaling. In contrast,
IL-10 did not affect anti-CD3/anti-CD28-induced IL-17 production from memory T cells
even in the presence of APC. This might have implications for the interpretation of ther-
apeutic trials in patients with chronic inflammation where Th17 cells contribute to
pathogenesis.
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Introduction
IL-10 was first described as a factor produced by Th2 cells, which
inhibits cytokine production by Th1 cells [1]. Since then it has
emerged that IL-10 is also produced by APC and that it can also
inhibit cytokine production by Th0 and Th2 cells. Nevertheless, it
is still unclear how exactly this inhibition is mediated on a
molecular level and whether all T-cell subpopulations are equally
affected by IL-10.
It has been demonstrated that a great amount of the inhibitory
activity of IL-10 on T cells is indirect and results from its effects
on APC. IL-10 down-regulates surface expression of MHC class II
and of several co-stimulatory molecules on APC, such as CD80/86
and ICAM-1, and thereby strongly impairs their antigen-
presenting capacity [2–4]. In addition, it influences the produc-
tion of several soluble mediators including IL-1, IL-6, IL-12, IL-18
and TNF-a [5–7], which support T-cell activation and differ-
entiation into Th1 cells. In line with this, we have previously
demonstrated that the inhibitory effect of IL-10 on cytokine-
induced IFN-g production by T cells is entirely dependent on the
presence of CD141 cells and that it can be overcome by the
addition of exogenous cytokines [8]. However, T cells express
IL-10 receptors and a few direct inhibitory effects of IL-10 on
naı¨ve T cells have been described, such as the inhibition of IL-2
production and more recently, the inhibition of CD28 signaling
[9–11]. A transient activation of SHP-1 by IL-10 was suggested to
mediate the inhibition of CD28 and also ICOS signaling [12].
Despite its broad anti-inflammatory profile, therapeutic trials
with IL-10 to dampen an ongoing chronic inflammation have
been largely disappointing (reviewed in [13]). The reasons for
this are rather unclear. Chronic inflammation is thought to be
driven by uncontrolled effector memory T-cell activation. It has
been suggested that IL-10 has no direct effects on antigen-primed
T cells because they would loose IL-10RI expression after
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activation [14]. In the past, many chronic inflammatory diseases
were linked with an excessive Th1 response, with IFN-g as the
detrimental effector cytokine. However, later reports demon-
strated that IFN-g is necessary for the activity of regulatory T cells
[15] and that it has also a role in limiting inflammation [16]. It
now emerges that excessive production of IL-17 from Th17 cells
might be an even more decisive factor in chronic inflammation
(reviewed in [17, 18]). Whereas several factors which negatively
regulate Th17 cell development have been described [19, 20], it
is unknown which factors can restrict an already established
memory IL-17 production.
Therefore, we analyzed the effect of IL-10 on various T-cell
subpopulations regarding their TCR-induced IFN-g and IL-17
production. In contrast to earlier reports [11, 12, 21], we found
that IL-10 can inhibit TCR-induced IFN-g production in freshly
isolated memory T cells in the absence of APC. However, we could
not detect any direct inhibitory effect on Th17 cells regarding their
anti-CD3-induced IL-17 production. Furthermore, in the presence
of APC, IL-10 had a lower capacity to inhibit antigen-induced IL-17
production compared with IFN-g production in T cells. These
results may help to understand why the success of IL-10 therapy in
an ongoing chronic inflammation has its limitations. IL-10 inhibits
IFN-g stronger then IL-17 after antigen presentation via APC.
Results
IL-10 inhibits IFN-c and to a lesser extent, IL-17 after
antigen presentation via APC
IL-10 is known to inhibit the production of a wide range of T-cell
cytokines by reducing antigen presentation and co-stimulation
mediated by APC. To test whether this also applies for IL-17
production, we compared the ability of IL-10 to inhibit antigen-
dependent production of IFN-g and IL-17, respectively. We
choose a fungal stimulus as antigen because they are known
inducers of IL-17. Therefore, we stimulated PBMC with Candida
albicans antigen in the absence or presence of IL-10 for 72 h
(Fig. 1A). Under these conditions, IL-10 can exert its inhibitory
effect on APC and T cells. Antigen-induced IFN-g and IL-17
production in the absence of IL-10 were comparable between IFN-g
and IL-17 with a median of around 350 pg/mL. As expected, IL-10
was able to inhibit both IFN-g and IL-17 production (each with
po0.05, Fig. 1A). However, the inhibitory effect on IFN-g
production was significantly stronger than on IL-17 production
(po0.05, Fig. 1A). This indicates that IL-10 might use different
mechanisms for inhibiting IFN-g and IL-17 production, respectively.
IL-10 interferes with TCR-induced IFN-c but not IL-17
in freshly-isolated PBMC
We next asked whether IL-10 would be able to inhibit IFN-g
and/or IL-17 production independently of its ability to down-
regulate antigen presentation and co-stimulatory molecules on
APC. Hence, we provided TCR- and co-stimulation through plate-
bound antibodies against CD3 and CD28. PBMC were stimulated
for 24 h in the presence or absence of IL-10 before IFN-g and
IL-17 production were measured in the supernatants by ELISA.
IL-10 significantly inhibited TCR-induced IFN-g production
(po0.05, Fig. 1B), but only had a weak and non-significant
inhibitory effect on IL-17 production (Fig. 1B). Similar effects
were seen on the mRNA level: IL-10 inhibited TCR-induced IFN-g
mRNA production by 80% (po0.05, Fig. 1C), but did not affect IL-
17 mRNA induction (Fig. 1C).
These data were confirmed by assessing intracellular cytokine
production in anti-CD3/anti-CD28-stimulated PBMC. For this, we
added Brefeldin A only during the last 6 h of TCR-stimulation in
order to avoid any interference of Brefeldin A with the inhibitory
activity of IL-10. IL-10 reduced the percentage of IFN-g-producing
CD41 as well as CD81 T cells, but did not affect IL-17-producing
T cells (Fig. 1D). IL-10 did not affect the activation of T cells in
general, as we saw no difference in the percentage of CD25-
expressing T cells in the presence or absence of IL-10 (data not
shown). Other T-cell activation markers such as HLA-DR, another
marker for acute activation and CD57, a marker for chronic
activation, were also largely unaffected by IL-10 (data not
shown).
Inhibitory effect of IL-10 on TCR-induced IFN-c is
independent of IL-2
IL-2 is an important cofactor for IFN-g production by enabling
mRNA transport and translation [22, 23]. Furthermore, it has
been reported that exogenous addition of IL-2 abrogates the
inhibitory effects of IL-10 on T-cell proliferation [10]. Indeed, we
could confirm that the presence of exogenous IL-2 abrogated the
anti-proliferative effect of IL-10 on T cells (Fig. 2A). In contrast, it
did-not influence the inhibitory effect of IL-10 on IFN-g
production (Fig. 2B). Furthermore, exogenous addition of IL-2
did neither influence IL-17 production in presence nor absence of
IL-10 (data not shown). These results pointed toward a so far
unknown direct effect of IL-10 on IFN-g production independent
of IL-2 repression. Furthermore, because the amount of IFN-g
induction was higher in the presence of IL-2, we decided to add
IL-2 throughout the following experiments.
IL-10 directly inhibits TCR-induced IFN-c production in
the absence of APC
The IL-10-induced inhibition on IFN-g production after direct
T-cell-stimulation with plate-bound anti-CD3/anti-CD28 mAb in
the presence and absence of exogenous IL-2 suggested an
(i) APC- and (ii) IL-2-independent mode of inhibition. However,
in our previous work, we demonstrated the necessity of CD141
monocytes for the inhibitory effect of IL-10 on cytokine-induced
IFN-g production by T cells [8]. We therefore wondered whether
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this is also the case for TCR-induced IFN-g production. Hence, we
depleted CD141 monocytes from freshly isolated PBMC and then
stimulated the remaining cells with anti-CD3/anti-CD28 mAb and
IL-2 in the presence or absence of IL-10 for 24 h. IL-10 strongly
inhibited TCR-induced IFN-g production also in the absence of
CD141 APC (po0.05, Fig. 3A). To exclude an effect of CD14
APC such as B cells, we further purified the CD14-depleted PBMC
by an additional step of CD41 selection. This procedure yielded
highly purified CD41 T cells (on average 99%). IL-10 still
significantly inhibited TCR-induced IFN-g production, even
though the effect was now less pronounced than with depletion
of CD141 APC alone (po0.05, Fig. 3A). Similar results were
obtained after MACSTM purification of CD41 T cells either by
direct CD41 selection or by CD4-untouched separation (data not
shown). The observed inhibitory effect of IL-10 was not due to an
inhibition of cell proliferation during the 24 h of stimulation, as
was confirmed by 3H-dTTP-incorporation (data not shown).
In conclusion, IL-10 had a direct inhibitory effect on TCR-
induced IFN-g production by CD41 T cells in the absence of APC
and the presence of IL-2.
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Figure 1. IL-10 does inhibit TCR-induced IFN-g but not IL-17 production in freshly isolated PBMC. (A) Human PBMC from healthy blood donors
were activated with C. albicans antigen for 72 h in the presence (white bars) or absence (gray bars) of IL-10 (10 ng/mL). Supernatants were collected
for IFN-g and IL-17 analyses by ELISA. The amount of IFN-g or IL-17 in the absence of IL-10 was set to 100% for each individual donor, and IL-10
inhibition related to it. The absolute values ranged from 173 to 4453 pg/mL for IFN-g and from 235 to 513 pg/mL for IL-17 in the non-inhibited
samples. Results shown are averages from five independent experiments (7SD). (B) Human PBMC from healthy blood donors were activated with
immobilised anti-CD3/anti-CD28 mAb (1 mg/mL each) and IL-2 (100 U/mL) for 24 h in the presence (white bars) or absence (gray bars) of IL-10 (10 ng/
mL). Supernatants were collected thereafter and IFN-g and IL-17 levels analyzed by ELISA. The amount of IFN-g or IL-17 after anti-CD3/anti-CD28
treatment in the absence of IL-10 was set to 100% for each individual donor, and IL-10 inhibition related to it. The absolute values ranged from 9.4
to 427 ng/mL for IFN-g and from 0.9 to 1.5 ng/mL for IL-17 in the non-inhibited samples. Results shown are averages from five independent
experiments (7SD). (C) Following the same stimulation setup as described for (B), RNA was extracted from cells and IFN-g and IL-17 mRNA levels
were determined by Real-Time RT-PCR and normalized to the expression of the house keeping gene HPRT. The amount of IFN-g or IL-17 mRNA
following anti-CD3/anti-CD28 treatment without IL-10 incubation (gray bars) was set to 100% for each individual sample and IL-10 inhibition
(white bars) related to this. Results shown are averages from five independent experiments (7SD). Significant differences as calculated by
Wilcoxon test (po0.05) are indicated by an asterisk (). (D) PBMC were TCR-stimulated for 24 h by anti-CD3/anti-CD28 mAb (1 mg/mL each) and
Brefeldin A added for the last 6 h. Cells were then stained with a mixture of CD3/CD4 and CD3/CD8 mAb, respectively, and intracellular IFN-g and
IL-17 production in CD41 and CD81 T cells was analyzed by flow cytometry. Data from one representative out of three experiments are shown.
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IL-10 inhibition of TCR-induced IFN-c is not overcome
by blocking SHP-1
In contrast to naı¨ve T cells, antigen-primed T cells do not need co-
stimulation for re-activation. Previous work suggested that IL-10
does not inhibit memory T cells, because T-cell proliferation
induced by anti-CD3 in the absence of co-stimulation was not
inhibited by IL-10 [11, 12, 21]. We therefore aimed to analyze
the effect of IL-10 on TCR-induced IFN-g and IL-17 production by
memory T-cell subpopulations.
First, we investigated the effect of IL-10 on freshly isolated
non-CD14-depleted and CD14-depleted PBMC that were TCR-
stimulated in the absence of co-stimulation. Under these
circumstances, only memory and effector T cells should produce
IFN-g. Surprisingly, IL-10 inhibited anti-CD3-induced IFN-g
production in non-CD14-depleted and CD14-depleted PBMC to a
similar extent as anti-CD3/anti-CD28-induced IFN-g production
(both with po0.05, Fig. 3B). The same results were obtained for
CD14-depleted and then CD41 re-purified T cells, which ruled
out an effect of contaminating APC (po0.05, Fig. 3B). On the
other hand, anti-CD3-induced IL-17 production was not inhibited
by IL-10 (data not shown). This suggested that IFN-g, but not
IL-17 production from memory T cells, was directly inhibited by
IL-10.
To confirm this, we repeated the experiments with CD41
memory (CD45RO1) and naı¨ve (CD45RA1) T-cell subpopula-
tions. Again, IL-10 inhibited IFN-g production in memory CD41
T cells to a similar extent as in highly re-purified CD41 cells
(po0.05, Fig. 3C) but had no effect on anti-CD3-induced IL-17
production (Fig. 3C). Presence or absence of exogenous IL-2 did
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Figure 2. Exogenous IL-2 abrogates IL-10 inhibition of T-cell prolifera-
tion but has no influence on IL-10-induced inhibition of IFN-g
production. (A) Human PBMC were labeled with CSFE and proliferation
was induced by TCR-stimulation with plate-bound anti-CD3/anti-CD28
mAb (1 mg/mL each) in the presence (bold lines) or absence (dotted
lines) of IL-10 (10 ng/mL) and IL-2 (100 U/mL) as indicated. The degree of
proliferation was assessed by analyzing the reduction of CSFE-label
after cell devision by flow cytometry. One representative out of three
experiments is shown. (B) Human PBMC were activated with immo-
bilised anti-CD3/anti-CD28 mAb (1 mg/mL each) in the presence (white
bars) or absence (gray bars) of IL-10 (10 ng/mL) and IL-2 (100 U/mL) as
indicated. Supernatants were collected thereafter and IFN-g produc-
tion analyzed by ELISA. The amount of IFN-g after anti-CD3/anti-CD28
treatment in the absence of IL-10 was set to 100% for each individual
donor, and IL-10 inhibition related to it. The absolute values ranged
from 2.7 to 87.6 ng/mL for IFN-g in the non-inhibited samples. Results
shown are averages from three independent experiments (7SD).
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Figure 3. IL-10 directly inhibits TCR-induced IFN-g production in the absence of APC and co-stimulation but has no influence on IL-17 production.
PBMC from healthy blood donors were either used directly or depleted with anti-CD14-coated magnetic beads (CD14). CD41 T cells were further
purified from CD14-depleted PBMC by CD41 selection to a purity of at least 99% (CD14CD41). For memory T-cell separation (C), CD41 cells were
purified from PBMC by CD4-untouched magnetic separation. Then CD45RO1 CD41 T cells were enriched by depleting CD45RA1 cells. These
different cell populations were activated with IL-2 (100 U/mL) and either (A) immobilised anti-CD3/anti-CD28 mAb (1mg/mL each), or (B, C)
immobilized anti-CD3 (1 mg/mL) for 24 h in the presence (white bars) or absence (gray bars) of IL-10 (10 ng/mL). Supernatants were collected
thereafter and (A, B) IFN-g production and (C) IFN-g and IL-17 production was analyzed by ELISA. The amount of cytokine after respective
stimulation without IL-10 was set to 100% for each individual donor and IL-10 inhibition related to this. In the absence of IL-10, the absolute values
for IFN-g (4–427 ng/mL for PBMC and 1.8–15.7 ng/mL for CD14-depleted and CD41 re-purified T cells) were comparable in the anti-CD3/anti-CD28-
stimulated and only anti-CD3-stimulated samples. In memory CD45RO1 CD41 T cells, in the absence of IL-10, the absolute values ranged from 4.6
to 15.5 ng/mL for IFN-g and from 0.05 to 1.4 ng/mL for IL-17. Results shown are averages from five independent experiments (7SD). Significant
differences as calculated by Wilcoxon test (po0.05) are indicated by an asterisk ().
Eur. J. Immunol. 2009. 39: 1066–1077 Immunomodulation 1069
& 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
not alter these results, and naı¨ve CD41 T cells did neither
produce significant amounts of IFN-g nor IL-17 (data not shown).
Naı¨ve and central memory T cells express CD28, but it
becomes down-regulated in effector memory or effector T cells
([24, 25], and data not shown). Recently, Joss et al. postulated
that the inhibitory effect of IL-10 on T cells is mediated via
inhibition of CD28 signaling, indicating that only CD281 T cells
would be inhibited by IL-10 [11]. To test this, we separated
CD28 and CD281 cells from CD14-depleted PBMC, and deter-
mined IFN-g concentrations in the supernatants of these cells
after TCR-stimulation by anti-CD3/anti-CD28 incubation.
Surprisingly, CD28 T cells produced a significant amount of
IFN-g after TCR-stimulation and were susceptible to inhibition
by IL-10 (Fig. 4A). This suggested that IL-10 also affects the
CD28 effector memory and effector T-cell subsets. To confirm
these data by another approach, we stained CD28 and intracel-
lular IFN-g in TCR-stimulated, CD14-depleted PBMC (Fig. 4B).
IL-10 reduced the number of IFN-g-producing T cells within the
CD28 T-cell population (3.1% of T cells compared with 8.3%) as
much as in the CD281 T-cell population (3.2% of T cells
compared with 7.0%) (Fig. 4B). However, IL-10 did not seem to
significantly alter the amount of IFN-g produced per cell (as
measured by MFI, data not shown). We also analyzed the effect
of IL-10 on IFN-g production by the T-cell subsets expressing the
activation markers CD25, HLA-DR and CD57, respectively.
Similar to the results for CD28, the inhibition of IFN-g production
by IL-10 was comparable in T-cell subsets either positive or
negative for these activation markers (data not shown).
In summary, in contrast to IL-17, TCR-induced IFN-g
production in CD41 memory T cells was inhibited by IL-10.
Furthermore, the ability of IL-10 to inhibit IFN-g production in
CD28 T cells suggests a molecular mechanism, which is inde-
pendent of CD28 co-stimulation.
IL-10 inhibition of TCR-induced IFN-c production is not
overcome by blocking SHP-1
A very recent study suggested that transient activation of the
tyrosine phosphatase SHP-1 mediates the inhibitory effect of
IL-10 on CD28- or ICOS-induced T-cell proliferation [12]. SHP-1
has also been described to interfere with TCR-induced ZAP-70
activation. Therefore, we wondered whether SHP-1 activation
also plays a role in mediating the inhibition of anti-CD3-induced
IFN-g production by IL-10. To address this question, we first
used the general phosphatase inhibitor pervanadate in our
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Figure 4. IL-10 inhibits TCR-induced IFN-g production independently from CD28 expression. (A) Antigen-primed CD28 T cells were isolated by a
two-step separation protocol. First, CD141 cells were depleted from PBMC and then CD281 cells were depleted from the remaining cells. The CD281
fraction was eluted for comparison. Then cytokine production was induced by immobilized anti-CD3/anti-CD28 (each 1 mg/mL) and IL-2 (100 U/mL)
in the presence (white bars) or absence (gray bars) of IL-10 (10 ng/mL). Results shown are averages from three independent experiments (7SD).
(B) CD14-depleted PBMC were stimulated for 30 h by immobilized anti-CD3 and anti-CD28 (each 1 mg/mL) and IL-2 (100 U/mL) in the presence or
absence of IL-10 (10 ng/mL). After addition of Brefeldin A 6 h prior to the end of culture, cells were stained for surface anti-CD3 and anti-CD28 and
intracellular IFN-g expression and analyzed by flow cytometry. CD3-gated T cells are depicted from one out of two experiments. Control cells
incubated with IL-10 only did not show IFN-g production (data not shown).
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experiments. Interestingly, non-stimulated T cells produced large
amounts of IFN-g in the presence of the inhibitor. In contrast,
TCR-induced IFN-g production was reduced to levels of IL-10
inhibition which both made it very difficult to interpretate these
results (data not shown).
We therefore next used the specific, irreversible SHP-1 inhi-
bitor sodium stibogluconate [26] to interfere only with SHP-1
activity. PBMC treated with this inhibitor did not produce IFN-g
spontaneously and responded normally toward TCR-stimulation.
Inhibition of SHP-1 did not overcome the effect of IL-10 on TCR-
induced IFN-g production (Fig. 5A). This was the case for TCR-
stimulation with anti-CD3 alone, as well as in the presence of
additional co-stimulation with anti-CD28 (Fig. 5A). Even higher
concentrations of sodium stibogluconate (50 mg/mL) did not
abrogate the IL-10 inhibitory effect (data not shown). The activity
of the inhibitor was shown by enhancement of IFN-a-induced
STAT-1 activation in T-cells (Fig. 5B). These data suggest that
IL-10 uses a SHP-1-independent mechanism for inhibiting
TCR-induced IFN-g production.
IL-10 inhibition of IFN-c is lost by in vitro culture
despite intact signalling
Next, we wondered whether recently activated T cells, which
occur in acute infection and to an even greater extent in chronic
inflammation, are susceptible to the inhibitory effect of IL-10 on
IFN-g production. It has been suggested that IL-10RI expression is
down-regulated after TCR activation [14], which should lead to a
loss of IL-10 responsiveness in recently activated T cells.
Therefore, we incubated PBMC for 24–48 h in the presence of
anti-CD3/anti-CD28 mAb and IL-2 to achieve pre-activation, and
then studied the influence of IL-10 on IFN-g production after
re-stimulation with anti-CD3 and anti-CD28 mAb. In agreement
with other reports, we did not observe an inhibitory effect of
IL-10 on IFN-g production by these freshly pre-activated T cells
(Fig. 6A). Surprisingly, T cells cultured in vitro without pre-
stimulation also lost their responsiveness toward IL-10. This led
us to the conclusion that the unresponsiveness to the inhibitory
effect of IL-10 on freshly pre-activated T cells is likely to be an
in vitro-culture artifact rather than a stimulation-induced effect.
Interestingly, despite the lack of an effect of IL-10 on IFN-g
production, the in vitro pre-activated T cells responded normally
to IL-10-induced SOCS-3 mRNA induction (Fig. 6B) and STAT3
activation (Fig. 6C).
Th17 cells have intact IL-10 signalling
As we could observe an inhibitory effect of IL-10 on IFN-g but not
on IL-17 production from freshly isolated antigen experienced
T cells, we next wondered whether Th17 cells might be
unresponsive to IL-10 because they would have, e.g. lost IL-10
receptor expression during differentiation. We tried to address
this question by measuring STAT3 activation in Th17 cells by
intracellular FACS-staining with phospho-specific antibodies after
20 min of IL-10 stimulation. Several surface markers have been
described to identify human Th17 cells with the IL-23 receptor
expressing CCR4/CCR6 double-positive T cells being highly
specific for IL-17 production [27–29]. We used therefore either
antibodies against surface IL-23 receptor on CD31 T cells or gated
for CCR4/CCR6 double-positive T cells to measure intracellular
STAT3 activation in Th17 cells by IL-10. Surprisingly, Th17 cells
mounted a normal STAT3 activation upon IL-10 stimulation
(Fig. 7A). In order to analyze IL-10 target gene expression in
Th17 cells, we enriched for Th17 cells by magnetic beads with
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Figure 5. Inhibition of SHP-1 does not abolish IL-10-induced inhibition
on TCR-stimulated IFN-g production. (A) Human PBMC from healthy
blood donors were left untreated or incubated with the irreversible
SHP-1 inhibitor sodium stibogluconate (10 mg/mL) for 10 min. The cells
were then activated with immobilised anti-CD3/anti-CD28 mAb (1 mg/
mL each) or anti-CD3 (1 mg/mL) and IL-2 (100 U/mL) for 24 h in the
presence (white bars) or absence (gray bars) of IL-10 (10 ng/mL).
Supernatants were collected thereafter and IFN-g analyzed by ELISA.
Because of donor-specific differences for absolute cytokine levels, the
amount of IFN-g after anti-CD3/anti-CD28 or anti-CD3 treatment was
set to 100% for each individual donor and IL-10 inhibition related to
this. In the absence of IL-10, the absolute values for IFN-g following
anti-CD3 stimulation ranged from 3 to 31.5 ng/mL and similar values
were obtained with anti-CD3/anti-CD28 stimulation and in the
presence of stibogluconate, respectively. Results shown are averages
from four independent experiments (7SD). (B) Freshly isolated PBMC
were either left untreated (thin line) or pre-incubated with the SHP-1
inhibitor sodium stibogluconate (10 mg/mL; bold line) for 10 min and
then treated with IFN-a for 2 h. PBMC without IFN-a treatment served
as control (dotted line). Cells were then fixed and lysed and STAT1-
phosphorylation was assessed by flow cytometry after co-staining of
surface CD3 expression and intracellular staining of p-STAT1.
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anti-IL-23R after CD14 depletion. Intracellular FACS-staining
revealed that indeed these CD31 IL-23R1 T cells are producers of
IL-17 and that they produce little, if any, IFN-g (Fig. 7B). In line
with the observation that IL-10 is able to induce STAT3 activation
in Th17 cells, we also observed an induction of its target gene
SOCS-3 in these IL-23R-enriched T cells (Fig. 7C). These results
together suggest that Th17 cells are fully responsive toward IL-10
but this does not result in inhibition of IL-17 production.
Discussion
The anti-inflammatory properties of IL-10 have been well
described in the past. It targets the induction of various
pro-inflammatory mediators as well as antigen presentation
and thereby indirectly inhibits T-cell responses. In vivo, the
lack of IL-10 in IL-10-deficient mice leads to the development of
chronic inflammation in the form of colitis [30]. Because of its
potent anti-inflammatory properties, IL-10 was used with high
expectations in therapeutic trials for a number of chronic
inflammatory diseases, which were thought to be driven by an
excessive Th1 response (reviewed in [13]). However, despite
some beneficial effects – particularly in psoriasis [31]– IL-10
therapy did not compare favorably to other biologicals, such as
for example, anti-TNF-a therapy. This was rather surprising
because IL-10 targets a wide range of inflammatory mediators in
addition to TNF-a.
However, most in vitro studies have described inhibitory
effects of IL-10 on the induction of an inflammatory immune
response, but not on an ongoing or chronic inflammation. We
therefore wanted to analyze whether IL-10 is able to inhibit an
already established memory or effector T-cell response. In
contrast to naı¨ve T cells, memory and effector T cells respond to
TCR engagement in the absence of co-stimulation. Furthermore,
effector cytokine production occurs rapidly within 24 h after
stimulation, because necessary epigenetic changes have already
been established [32, 33]. To our surprise, IL-10 was able to
directly inhibit TCR-induced IFN-g production in memory T cells.
This was evident from several observations: (i) The time frame
for IFN-g production in our direct TCR-triggered model was 24 h.
Within this time frame, mainly memory and effector T cells
respond, because naı¨ve T cells have to proliferate first before they
can produce IFN-g. (ii) In contrast to previous reports on prolif-
eration [11, 12], IL-10 inhibited IFN-g production induced by
anti-CD3 cross-linking without co-stimulation – a condition
where only memory T cells should respond. (iii) In agreement
with this, under the same conditions, isolated memory T cells
(either CD41 CD45RO1 T cells or CD28 effector/effector
memory T cells) were inhibited by IL-10. (iv) Intracellular
staining for IFN-g production revealed that all of the investigated
T-cell subsets were susceptible to inhibition by IL-10, including
T cells with activation and memory markers. The latter is espe-
cially interesting with respect to CD28 T cells, as uncoupling of
CD28 signaling has been suggested to mediate the direct inhibi-
tory effect of IL-10 on T cells [11, 12]
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Figure 6. Loss of IFN-g inhibitory effect of IL-10 after in vitro culture.
(A) PBMC were either left untreated for 24 h (24 h medium) or pre-
activated with immobilised anti-CD3/anti-CD28 mAb (1mg/mL each) and
IL-2 (100 U/mL) for 24 h (24 h anti-CD3/anti-CD28) followed by overnight
starvation in 0.5% FCS-containing medium and washing. Production
of IFN-g was induced by immobilised 24 h anti-CD3/anti-CD28 mAb
(1mg/mL each) or anti-CD3 (1mg/mL) and IL-2 (100 U/mL) for 24 h in the
presence (white bars) or absence (gray bars) of IL-10 (10 ng/mL). As a
positive control, freshly isolated PBMC from the same donor were
stimulated directly. Supernatants were collected thereafter and IFN-g
measured by ELISA. The amount of IFN-g after 24 h anti-CD3/anti-CD28
or anti-CD3 treatment was set to 100% for each individual donor and
IL-10 inhibition was related to this. The absolute values for IFN-g ranged
from 9 to 115ng/mL in the absence of IL-10 and were similar between
freshly prepared and pre-treated cells. Results shown are averages from
three independent experiments (7SD). (B) CD14-depleted PBMC were
either used freshly prepared or pre-activated (24 h anti-CD3/anti-CD28)
as described in (A). The cells were then either left untreated (gray bars)
or incubated with IL-10 (10 ng/mL) for 1 h (white bars). Afterwards, CD31
cells were isolated and RNA was extracted from these cells. SOCS-3
levels were determined using Real-Time RT-PCR with HPRT as reference
panel. The SOCS-3 mRNA levels of cells in the absence of IL-10 were set
as 1 and the IL-10 induction of SOCS-3 related to this. Results shown are
averages from two independent experiments (7SD). (C) Freshly isolated
or 24 h anti-CD3/anti-CD28 pre-activated CD14-depleted PBMC as
described in (A) were either left untreated (dotted lines) or incubated
with IL-10 (10 ng/mL) in serum-free medium for 5 min (bold lines). Cells
were then fixed and lysed and STAT3-phosphorylation was assessed by
flow cytometry after co-staining of surface CD4 expression and
intracellular staining of p-STAT3.
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We furthermore showed that inhibition of anti-CD3-induced
IFN-g production by IL-10 (i) is independent from APC, which is
in contrast to IL-12/IL-18-induced IFN-g production [8], and
(ii) is independent from IL-2 inhibition which was suggested to
be another mechanism by which IL-10 directly inhibited T cells
[9, 10, 34]. Fitting to the missing effect of IL-10 on IL-17
production (see below), receptor-proximal signaling events by
IL-10 were not abrogated by the selective SHP-1 inhibitor stibo-
gluconate, and we hypothesize a specific direct inhibitory
mechanism of IL-10 on TCR-mediated IFN-g production inde-
pendent from (i) CD28 signaling, and (ii) inhibition of IL-2
production, which remains to be elucidated.
In contrast to IFN-g, TCR-induced IL-17 production was
unaffected by IL-10. Interestingly, Th17 cells did respond toward
IL-10 stimulation with the activation of STAT3 excluding
general unresponsiveness of Th17 cells toward IL-10. It has
remained elusive why IL-10 therapy in chronic inflammatory
diseases has been rather disappointing. In recent years,
evidence is emerging that IL-17 production by Th17 cells, rather
than IFN-g production by Th1 cells, greatly accounts for the
pathology in chronic inflammation (reviewed in [17, 18]). Our
data suggest that the ability of IL-10 to stop a chronic inflam-
mation caused by Th17 memory cells might be limited. However,
it is well established that IL-10 can repress the production
of major inducers of a Th17 response. IL-10 inhibits IL-6
expression [6] and the expression of the common p40 subunit [7]
shared by IL-12 and IL-23 [35]. Interestingly, colitis caused by
IL-10 deficiency can be prevented by depleting IL-23 [36]
demonstrating that IL-10 can control the induction of an
inflammatory IL-17 response. In contrast to IL-6 and IL-23, IL-10
does not inhibit TGF-b production but rather induces its activity
[37, 38] and TGF-b has been associated with the generation of
regulatory T cells (reviewed in [39]). Thus we speculate that
although IL-10 may only partly be able to interfere with an
already established inflammatory process, it may favor the
induction of regulatory T cells instead of Th17 cells in the
primary response to an inflammatory stimulus. Compatible with
this hypothesis are findings in psoriatic patients treated with
IL-10 for relapse prevention: a significant, decreased relapse rate
could be seen, indicating that IL-10 application may be successful
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in preventing rather than in reverting an already established
inflammatory immune response [40].
In conclusion, our results suggest that in contrast to inhibition
of Th1 responses, IL-10 has its limitation in inhibiting an already
established and ongoing Th17-driven chronic inflammation.
Taken together with data published by other groups, IL-10
however may be able to prevent the induction of a Th17
response. These results should have implications for the ther-
apeutic use of IL-10 in inflammatory diseases. Firstly, they
suggest that IL-10 therapy should be promising for inflammatory
diseases that are solely caused by an ongoing excessive Th1
response. Secondly, it might be still possible to use IL-10 in Th17-
driven diseases, but only in combination with conventional or
anti-TNF therapy stopping the ongoing inflammatory process. In
that case, IL-10 should be able to prevent a relapse.
Materials and methods
Cell culture and stimulation
Human PBMC were isolated from citrate anti-coagulated blood of
healthy volunteers by Ficoll-Paque density gradient centrifuga-
tion and cultured at a cell density of 1 106 cells/mL in Roswell
Park Memorial Institute 1640 medium supplemented with FCS
(10% v/v), L-glutamine (2 mM) and penicillin/streptomycin
(each at 10 000 U/mL) (all Biochrom KG, Germany). All healthy
volunteers participated on a voluntary basis and gave written
informed consent.
Antigen-dependent stimulation of cytokine production was
performed by stimulating PBMC (2 106/mL) with C. albicans
(dilution of 1/1000; Stallergenes GmbH, Germany) in the
presence or absence of IL-10 (10 ng/mL; R&D Biosystems,
Germany). After 72 h, supernatants were harvested and IFN-g
and IL-17 concentrations were determined using commercially
available ELISA (R&D Biosystems). For TCR-induced cytokine
production, PBMC or isolated T cells (1106 cells/mL) were
stimulated with plate-bound anti-CD3 (OKT3, 1mg/mL; Jansen-
Cilag GmbH, Germany) alone or when indicated in combination
with plate-bound anti-CD28 (L293, 1 mg/mL; BD Bioscience,
Germany) and IL-2 (100 IU/mL; R&D Biosystems) in the presence
or absence of IL-10 (10 ng/mL). After 24 h, supernatants were
harvested and IFN-g and IL-17 concentrations were determined
using commercially available ELISA (R&D Biosystems).
If pre-activated PBMC were used, PBMC were pre-stimulated
for 24 h with immobilized anti-CD3/anti-CD28 mAb (1mg/mL
each) and IL-2 (100 IU/mL). They were then washed and starved
overnight in Roswell Park Memorial Institute medium containing
0.5% FCS v/v before being re-stimulated with anti-CD3/anti-
CD28 mAb in the presence or absence of IL-10 (10 ng/mL). As
control, instead of pre-stimulation, cells were left untreated for
24 h and then re-stimulated under the same conditions. Twenty-
four hours after re-stimulation, cells were harvested and super-
natants were analyzed for IFN-g or IL-17 production by ELISA.
Cell separation
Monocytes were depleted from PBMC by using anti-CD14-coated
magnetic MACSTM beads (Miltenyi Biotech GmbH, Germany)
following the manufacturer’s protocol. Cell purity was confirmed
by flow cytometry (CD141 cellso0.5%). For highly purified
CD41 T cells, CD14-depleted PBMC were re-purified with
anti-CD4-coated MACSTM beads (Miltenyi Biotech GmbH).
Purity of CD41 T cells was 499% in the life cell gate. For
isolation of CD41 memory T cells, first CD41 T cells were
separated from PBMC with CD4-untouched MACSTM beads and
then further separated either for CD45RO1 cells (memory CD41
T cells) via depletion of CD45RA1 cells or for CD45RA1 cells
(naı¨ve CD41 T cells) via depletion of CD45RO1 cells using the
MACSTM system (Miltenyi Biotech GmbH). Separation of CD28
and CD281 cells was performed with anti-CD28-coated MACSTM
beads (Miltenyi Biotech GmbH) after CD14 depletion from
PBMC. Separation of IL-23R1 cells was performed with anti-
FITC-coated MACSTM beads (Miltenyi Biotech GmbH) after CD14
depletion from PBMC and labeling with anti-IL-23R-FITC anti-
body (R&D Biosystems).
Measurement of PBMC proliferation with CFSE
PBMC were re-suspended at 1107 cells/mL in PBS containing
5mM CFSE (Molecular Probes/Invitrogen, USA). After 5 min
incubation at room temperature, cells were washed twice with
culture medium. Then cells were stimulated at a concentration of
1 106 cells/mL with immobilized anti-CD3 Ab (1 mg/mL) and
anti-CD28 Ab (1 mg/mL), with or without IL-2 (100 U/mL), in the
presence or absence of IL-10 (10 ng/mL) for 5 days. Cells were
finally analyzed using a FACScalibur flow cytometer (Becton
Dickinson, Germany) and CellQuest software (Becton Dickinson).
Analysis of intracellular cytokine production by flow
cytometry
PBMC (2 106) or respective isolated T-cell subsets were
stimulated with immobilized anti-CD3/anti-CD28 (each at
1mg/mL) and IL-2 (100 U/mL), in the presence or absence of
IL-10 (10 ng/mL) for 30 h. After 24 h, Brefeldin A (10 mg/mL;
Sigma, Germany) was added for the last 6 h. For analysis
of IL-23R1 T cells, PBMC were stimulated with PMA (10 ng/
mL; Sigma), ionomycin (0.5 mg/mL; Sigma) and Brefeldin
A for 15 h. Following stimulation, cells were harvested, washed
in PBS and incubated for 30 min at 41C in the dark with the
following monoclonal antibodies: anti-HLA-DR (L243; Becton
Dickinson), anti-CD3 (SK7; Becton Dickinson), anti-CD8
(SK1; Becton Dickinson), anti-CD25 (2A3; Becton Dickinson),
anti-CD57 (NC1; Beckman-Coulter), anti-CD28 (CD28.2;
Beckman-Coulter), anti-CD4 (SK3; Becton Dickinson), anti-
CD45RO (Leu-45RO; Becton Dickinson), anti-CD45RA (HI100;
Becton Dickinson), anti-IL-23R (R&D Biosystems). Fluorochrome
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combinations were chosen to allow for analysis of co-staining of
respective antigens. All antibodies were used in saturating
amounts. Cells were then washed once in PBS containing
2% v/v FCS and 0.1% w/v NaN2 prior to fixation and permeabi-
lization with 500mL Cytofix/Cytoperm solution (Becton Dick-
inson) for 10 min at room temperature in darkness. Cells were
washed once again and incubated with blocking buffer (100 mL
PBS/10% v/v human AB serum; both Sigma) for 20 min at 41C in
the dark to prevent unspecific binding of the anti-cytokine
monoclonal antibody. After another washing step, 10 mL of anti-
IFN-g-FITC (25723.11; Becton Dickinson) or anti-IL-17A-PE
(eBio64DEC17; eBioscience, Germany) were added and cells
were incubated for 30 min at 41C in darkness followed by a final
washing step prior to measurement. Measurement was done
using four-color flow cytometry on a FACS Calibur (Becton
Dickinson; at least 50 000 CD31 lymphocytes were collected).
Data were analyzed using CellQuest (Becton Dickinson). T-cell
gating was done using side scatter and CD3-staining properties.
Analysis of phospho-STAT3 and phospho-STAT1
induction by flow cytometry
Freshly isolated PBMC or pre-activated PBMC (of the same
donor) were incubated for 20 min with or without IL-10 (10 ng/
mL). Then cells were stained with anti-IL-23 R-FITC and fixed
with Cytofix Buffer (Becton Dickinson) for 10 min at 371C and
permeabilized with Phosflow Perm Buffer (Becton Dickinson) for
30 min on ice. For surface staining of CCR4 and CCR6, PBMC
were first stained with anti-CCR6-PE (11A9, Becton Dickinson)
and anti-CCR4-FITC (R&D Biosystems) and then incubated for
20 min with or without IL-10 (10 ng/mL), fixed with Cytofix
Buffer for 10 min at 371C and permeabilized with Phosflow Perm
Buffer for 30 min on ice.
For induction of STAT1 tyrosine phosphorylation, PBMC were
incubated with IFN-a2a (0.1 ng/mL; Miltenyi Biotech GmbH) for
2 h, then fixed with Cytofix Buffer for 10 min at 371C and
permeabilized with Phosflow Perm Buffer for 30 min on ice.
Cells were washed and anti-CD3-PerCP (SK7, Becton Dickinson)
and anti-Stat3 (pY705)-PE (4/P Stat3, Becton Dickinson)
or anti-Stat3 (pY705)-FITC (4/P Stat3, Becton Dickinson) or anti-
Stat1 (pY701)-FITC (Becton Dickinson) were added and incu-
bated for 30 min at room temperature in the dark. Cells were
analyzed using a FACS Calibur flow cytometer and CellQuest
software.
Analysis of cytokine and SOCS-3 mRNA induction
Total RNA was isolated for cytokine mRNA quantification with
Absolute mRNA Micro Kits (Stratagene, Germany) after 24 h
of TCR-stimulation by immobilized anti-CD3/anti-CD28 (each
1mg/mL) in the presence or absence of IL-10 (10 ng/mL). mRNA
was transcribed into cDNA with Moloney murine leukemia virus
Reverse Transcriptase (Gibco BRL, US) and oligodT Primers (GE
Healthcare, Germany). Quantitative Real-Time RT-PCR for IFN-g
and IL-17 was performed with specific primers and probes from
Applied Biosystems (Germany) using the ABI prism 7700
sequence detector (Applied Biosystems) and hypoxanthine
phosphoribosyltransferase (HPRT) as reference panel. For analy-
sis of SOCS-3 induction, PBMC were stimulated with anti-CD3/
anti-CD28 (1 mg/mL) and IL-2 (100 U/mL) for 24 h. They were
then washed and starved overnight before stimulation with anti-
CD28 and/or anti-CD3 mAb in the presence or absence of IL-10
(10 ng/mL). Cells were harvested after 1 h, CD31 cells were
isolated by magnetic MACSTM beads and total RNA was extracted
from these cells. For analysis of SOCS-3 induction in separated
IL-23R1 cells, the cells were stimulated with anti-CD3/anti-CD28
mAb in the presence or absence of IL-10 (10 ng/mL) for 1 h and
then total RNA was extracted. SOCS levels were determined after
reverse transcription by Real-Time RT-PCR with HPRT as
reference panel. SOCS-3 sense: ctttctgatccgcgacagct, SOCS-3
anti-sense: tcacactggatgcgcaggt, SOCS-3 probe: ccagcgccacttctt-
cacgctcag.
Statistical analysis
If not stated otherwise, data are presented as mean7SD values.
For ELISA data, cytokine production of TCR-stimulated cells was
set at 100% in each individual experiment. All other samples
from the same experiment were expressed as percentages relating
to this. This was done because of large inter-individual variations
in absolute cytokine levels. The average and standard deviation
was determined from 3–5 independent experiments. Statistical
analysis was done for experiments with at least five independent
donors by using the Wilcoxon matched-pairs signed-ranked test
and SPSS software (USA). p-values (two-tailed) below 0.05 were
considered as significant.
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